Abstract
This article presents two QSAR studies on the novel series of HIV-1 protease inhibitors incorporating N-phenyloxazolidinone-5-carboxamides into the (hydroxyethylamino) sulfonamide scaffold as P2 ligands. All the statistical calculations have been done using PRECLAV software. A heuristic algorithm selects the best multiple linear regression (MLR) equation according to the highest leave-one-out cross-validation correlation coefficient. In the first QSAR study, only the Quantum Chemical descriptors have been used. The correlation between the observed values and the calculated values of activity is good (r 2 = 0.935, Se = 0.3782, r 2cv = 0.900, F = 76.6568). The second QSAR study has used both quantum chemical descriptors and topological finger print descriptors. The correlation between the observed values and the calculated values of activity is very good (r 2 = 0.9638, Se = 0.2823, r 2cv = 0.9492, F = 141.8338). The virtual molecular fragments that lead to a significant increase of the inhibitor activity are CH3 and CH. The virtual fragments C4H3S and C6H2 lead to significant decreases in the inhibitory activity. The results are critically discussed using Ridge statistics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ali A, Reddy GS, Cao H, Anjum SG, Nalam MN, Schiffer CA, Rana TM (2006) Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J Med Chem 49:7342–7356
Allinger NL (1977) Conformational analysis 130 MM2 A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc 99:8127
Appelt K (1993) Crystal structure of HIV-1 protease-inhibitor complexes. Perspect Drug Discov Des 1:23
Babine RE, Bender SL (1997) Molecular recognition of proteinminus signligand complexes: applications to drug design. Chem Rev 97:1359
Boehme RE, Borthwick AD, Wyatt PG (1995) Antiviral agents. Annu Rep Med Chem 30:139
Burkert U, Allinger NL (1982) Molecular mechanics ACS monograph 177. Am Chem Soc, Washington, DC
Carhart RE, Smith DH, Ventakataraghavan R (1985) Atom pairs as molecular features in structure-activity studies: definition and applications. J Chem Inf Comput Sci 25:64–73
Charterjee S, Hadi AS, Price B (2000) Regression analysis by examples, 3rd edn. Wiley, New York
De Clercq E (1995) Antiviral therapy for human immunodeficiency virus infections. J Clin Microbiol Rev 8:200–239
HyperCube Inc (2006) HyperChem release7.52 for windows Florida Science and Technology Park, USA
Irby RB, Yeatman TJ (2000) Role of src expression and activation in human cancer. Oncogene 19:5636
Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE (2003) Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134:221
Ivanciuc O, Ivanciuc T, Balaban Alexandru T (2002) QSAR models for the dermal penetration of polycyclic aromatic hydrocarbons. Internet Electron J Mol Des 1:566
Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J (1995) Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31–8959. Virology 206:527
Mitsuya H, Erickson J (1999) Discovery and development of antiretroviral therapeutics for HIV infection. In: Merigan TC, Bartlett JG, Bolognesi D (eds) Text book of AIDS medicine. Williams & Wilkins, Baltimore, p 751
Montgomery Douglas C, Peck Elizabeth A, Vining Geoffrey G (2006) Introduction to linear regression analysis, 4th edn. Wiley, New York
Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresh DA (2001) Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 7:222
Singh S (2009) Comparative QSAR studies on the novel series of thiazolones and tetrazole derivatives as HCV NS5B polymerase allosteric inhibitors. Lett Drug Des Discov 6:286–297
Singh S, Khadikar Padmakar V, Scozzafava A, Supuran Claudiu T (2009) QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software. J Enzym Inhib Med Chem 24:337–349
Stewart JJP (2007) The Mopac program is available from http://www.openmopac.net/
Summay JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337
Susva M, Missbach M, Green J (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 21:489
Talamonti MS, Roh MS, Curely SA, Gallick GE (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91:53
Talete srl (2007) DRAGON Plus for windows software for molecular descriptor Calculations Version 5.5-http://www.talete.mi.it/
Tarko L (2004) A procedure for virtual fragmentation of molecules into functional groups. ARKIVOC xiv:74–82
Tarko L (2005) Calcule QSPR/QSAR cu ajutorul programului PRECLAV. Rev Chim (Bucuresti) 56:639
Tarko L (2007) QSAR studies regarding the inhibition of the carbonic anhydrase by the sulfonamides containing a picolinoyl. Group Rev Chim (Bucuresti) 58:191
Tarko L (2008) The PRECLAV v.0809 program is available from the Center of Organic Chemistry (CCO), Romanian Academy, Bucharest
Tarko L (2008b) Aromatic molecular zones and fragments. ARIKIVOC xi:24–45
Tarko L, Supuran Claudiu T (2007) QSAR studies for the inhibition of the transmembrane isozymes XII and XIV of human carbonic anhydrase with a series of sulfonamides. Bioorg Med Chem 15:5666–5671
Tarko L, Lupescu I, Groposila-Constantinescu D (2005) Sweetness power QSARs by PRECLAV software. ARKIVOC X:254
Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 113:885
Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast Robert C, Mills Gordon B, Gallick Gary E (2003) Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88:73–79
Wlodawer A, Ericson JW (1993) Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 62:543
Yeatman T (2004) A renaissance for SRC. J Nat Rev 4:470
Acknowledgments
One of the Author (Shalini Singh) expresses her thanks to the Department of Science & Technology, Government of India, New Delhi, for awarding DST project SR/WOS-A/CS-61/2004 under Woman Scientists scheme, and to Dr. R.P. Singh, Principal, Bareilley College, Bareilley, India for his personal interest, encouragement and for providing facilities for carrying out this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, S., Singh, S. & Shukla, P. Modeling of novel HIV-1 protease inhibitors incorporating N-Aryl-oxazolidinone-5-carboxamides as P2 ligands using quantum chemical and topological finger print descriptors. Med Chem Res 20, 1556–1565 (2011). https://doi.org/10.1007/s00044-010-9416-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-010-9416-0